Trials / Completed
CompletedNCT03040713
Flortaucipir PET Imaging in Subjects With FTD
18F-AV-1451 PET Imaging in Subjects With Frontotemporal Dementia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Avid Radiopharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to assess the usefulness of flortaucipir in Positron Emission Tomography (PET) imaging for subjects diagnosed with Frontotemporal Dementia (FTD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flortaucipir F18 | 370 megabecquerel (MBq)(10 millicurie \[mCi\]) injection, single dose |
| PROCEDURE | Brain PET scan | positron emission tomography (PET) scan of the brain |
Timeline
- Start date
- 2017-04-11
- Primary completion
- 2018-10-24
- Completion
- 2018-10-24
- First posted
- 2017-02-02
- Last updated
- 2020-09-25
- Results posted
- 2020-09-25
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03040713. Inclusion in this directory is not an endorsement.